ResearcherFirst Affiliated Hospital of Dalian Medical UniversityActive in the last 2 years
Hong Xiang
Matched on ORCID iD 0000-0001-7827-3592; OpenAlex author ID A5101441966. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 2 papers
Papers 6
- Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1. Last author DOI 10.1038/s41420-024-01806-w↗
- Prospect of Gold Nanoparticles in Pancreatic Cancer. Last author DOI 10.3390/pharmaceutics16060806↗
- Metabolic reprogramming of immune cells in pancreatic cancer progression. Co-author DOI 10.1016/j.biopha.2022.113992↗
- Advances in targeted therapy for pancreatic cancer. Co-author DOI 10.1016/j.biopha.2023.115717↗
- Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. First author DOI 10.1016/j.phrs.2021.105595↗
- T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer? Co-author DOI 10.3389/fonc.2020.00382↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xufeng Tao · 5 shared papers, 2020–2024 · strength 0.88
- Paper Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement… DOI 10.1038/s41420-024-01806-w↗
- Paper Advances in targeted therapy for pancreatic cancer. DOI 10.1016/j.biopha.2023.115717↗
- Paper Metabolic reprogramming of immune cells in pancreatic cancer progression. DOI 10.1016/j.biopha.2022.113992↗
- Dong Shang · 3 shared papers, 2021–2024 · strength 0.67
- Paper Prospect of Gold Nanoparticles in Pancreatic Cancer. DOI 10.3390/pharmaceutics16060806↗
- Paper Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement… DOI 10.1038/s41420-024-01806-w↗
- Paper Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. DOI 10.1016/j.phrs.2021.105595↗
- Deshi Dong · 3 shared papers, 2023–2024 · strength 0.60
- Paper Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement… DOI 10.1038/s41420-024-01806-w↗
- Paper Advances in targeted therapy for pancreatic cancer. DOI 10.1016/j.biopha.2023.115717↗
- Paper Metabolic reprogramming of immune cells in pancreatic cancer progression. DOI 10.1016/j.biopha.2022.113992↗
- Fangyue Guo · 2 shared papers, 2020–2024 · strength 0.37
- Tianyi Yin · 1 shared paper, 2024 · strength 0.28
- Yu Wu · 1 shared paper, 2024 · strength 0.24
- Lin Xing · 1 shared paper, 2023 · strength 0.18
- Yue Pan · 1 shared paper, 2021 · strength 0.15
- Gary Guishan Xiao · 1 shared paper, 2021 · strength 0.15
- Junchao Guo · 1 shared paper, 2021 · strength 0.15
- Ge Gao · 1 shared paper, 2021 · strength 0.15
- Qi Zhou · 1 shared paper, 2020 · strength 0.13
- Dong Shang · 1 shared paper, 2020 · strength 0.13
- Shilin Xia · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.